Abstract:Background: Numerous studies have indicated that the neddylation pathway is closely associated with tumor development. MLN4924 (Pevonedistat), an inhibitor of the NEDD8-activating E1 enzyme, is considered a promising chemotherapeutic agent. Recently, we demonstrated that neddylation of the tumor suppressor PTEN occurs under high glucose conditions and promotes breast cancer development. It has been shown, however, that PTEN protein levels are reduced by 30–40% in breast cancer. Whether this PTEN deficiency affects the anti-tumor function of MLN4924 is unknown. Methods: In the present study, cell counting kit-8 and colony formation assays were used to detect cell proliferation, and a transwell system was used to quantify cell migration. A tumor growth assay was performed in BALB/c nude mice. The subcellular location of PTEN was detected by fluorescence microscopy. The CpG island of the UBA3 gene was predicted by the Database of CpG Islands and UCSC database. Western blotting and qRT-PCR were used to measure the expression of indicated proteins. The Human Protein Atlas database, the Cancer Genome Atlas and Gene Expression Omnibus datasets were used to validate the expression levels of UBA3 in breast cancer. Results: Our data show that the anti-tumor efficacy of MLN4924 in breast cancer cells was markedly reduced with the deletion of PTEN. PI3K/Akt signaling pathway activity correlated positively with UBA3 expression. Pathway activity correlated negatively with NEDP1 expression in PTEN-positive breast cancer patients, but not in PTEN-negative patients. We also demonstrate that high glucose conditions upregulate UBA3 mRNA by inhibiting UBA3 promoter methylation, and this upregulation results in the overactivation of PTEN neddylation in breast cancer cells. Conclusion: These data suggest a mechanism by which high glucose activates neddylation. PTEN is critical, if not indispensable, for MLN4924 suppression of tumor growth; PTEN status thus may help to identify MLN4924-responsive breast cancer patients.

NEDD8-Activating Enzyme Inhibitor MLN4924 Inhibits Both the Tumor Stroma and Angiogenesis in Pancreatic Cancer Via Gli1 and REDD1

Neuropilin-2–Mediated Tumor Growth and Angiogenesis in Pancreatic Adenocarcinoma

AKT Inhibitor MK-2206 Sensitizes Breast Cancer Cells to MLN4924, a First-in-class NEDD8-activating Enzyme (NAE) Inhibitor

Radiosensitization of Human Pancreatic Cancer Cells by MLN4924, an Investigational NEDD8-Activating Enzyme Inhibitor

Suppression of tumor angiogenesis by targeting the protein neddylation pathway.

Inhibition of Neddylation Modification Sensitizes Pancreatic Cancer Cells to Gemcitabine.

Gene Expression Profiling Reveals the Genomic Changes Caused by MLN4924 and the Sensitizing Effects of NAPEPLD Knockdown in Pancreatic Cancer.

Blockage of Neddylation Modification Stimulates Tumor Sphere Formation in Vitro and Stem Cell Differentiation and Wound Healing in Vivo

PD-L1 Induction Via the MEK-JNK-AP1 Axis by a Neddylation Inhibitor Promotes Cancer-Associated Immunosuppression

Neddylation-Independent Activities of MLN4924

Neddylation inhibitor MLN4924 suppresses growth and migration of human gastric cancer cells

Data from The Nedd8-Activating Enzyme Inhibitor MLN4924 Induces Autophagy and Apoptosis to Suppress Liver Cancer Cell Growth

MicroRNA-145 Suppresses Cell Proliferation, Invasion and Migration in Pancreatic Cancer Cells by Targeting NEDD9.

The Double-Edged Effects of MLN4924: Rethinking Anti-Cancer Drugs Targeting the Neddylation Pathway

The Absence of PTEN in Breast Cancer Is a Driver of MLN4924 Resistance

Neural Precursor Cell Expressed, Developmentally Downregulated 8-Activating Enzyme Inhibitor Mln4924 Sensitizes Colorectal Cancer Cells to Oxaliplatin by Inducing Dna Damage, G2 Cell Cycle Arrest and Apoptosis

Suppression of Glioblastoma by Targeting the Overactivated Protein Neddylation Pathway.

Chk1 Inhibitor SCH 900776 Enhances the Antitumor Activity of MLN4924 on Pancreatic Cancer

Radiosensitization by the investigational NEDD8-activating enzyme inhibitor MLN4924 (pevonedistat) in hormone-resistant prostate cancer cells.

A New Facet of NDRG1 in Pancreatic Ductal Adenocarcinoma: Suppression of Glycolytic Metabolism.

Pevonedistat Suppresses Pancreatic Cancer Growth via Inactivation of the Neddylation Pathway